Ariad opts for genome profiling to advance NSCLC product
This article was originally published in Scrip
Executive Summary
In a bold move Massachusetts-based Ariad Pharmaceuticals is partnering with Foundation Medicine, a molecular information company, to use genomic profiling to identify the optimal patient population for its investigational non-small cell lung cancer drug AP26113. Even though genomic profiling has been available for some time, few companies have used it to develop their regulatory approval submissions.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.